Clinical Trial

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-16.
Trial Details
NCT Number NCT07238686
Lead Sponsor Beijing 302 Hospital
Conditions Myelodysplastic Syndromes
Enrollment 40 participants
Start Date 2025-06-20
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-25